Bristol Myers Squibb (BMY) Assets Average (2009 - 2026)

Bristol Myers Squibb has disclosed Assets Average across 17 years of filings, most recently posting $88.3 billion for Q1 2026.

• In Q1 2026, Assets Average fell 4.6% year-over-year to $88.3 billion; the TTM figure through Mar 2026 stood at $88.3 billion (down 4.6% YoY), while the FY2025 annual figure was $91.3 billion, down 2.73% from the prior year.
• Assets Average retreated to $88.3 billion in Q1 2026, from $93.5 billion in the prior quarter.
• Over the last five years, Assets Average for BMY reached as high as $106.2 billion in Q1 2022 and fell as low as $88.3 billion in Q1 2026.
• The 5-year median for Assets Average is $94.2 billion (2024), against an average of $95.6 billion.
• Annual changes were most pronounced in 2022 — Assets Average decreased 11.44% — and 2024, when it climbed 3.15%.
• A 5-year view of Assets Average shows it stood at $97.5 billion in 2022, then retreated by 4.41% to $93.2 billion in 2023, then fell by 0.08% to $93.1 billion in 2024, then grew by 0.35% to $93.5 billion in 2025, then decreased by 5.57% to $88.3 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $88.3 billion, $93.5 billion, and $95.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.